Lexaria Bioscience Corp.

NasdaqCM LEXX

Lexaria Bioscience Corp. Operating Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2024

Lexaria Bioscience Corp. Operating Cash Flow is NA for the Trailing 12 Months (TTM) ending November 30, 2024. Operating cash flow is cash generated from the company’s regular business operations.

Lexaria Bioscience Corp. Operating Cash Flow for the Trailing 12 Months (TTM) ending November 30, 2022 was USD -4.95 M.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: LEXX

Lexaria Bioscience Corp.

CEO	Mr. Michael Shankman CPA
IPO Date	Jan. 12, 2021
Location	Canada
Headquarters	100 – 740 McCurdy Road
Employees	5
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Biotechnology Clinical Trials Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Vaccines

Description

Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Key trends

Past 5 years